FLT3 and acute myeloid leukemia: A randomized, placebo-controlled phase III study of 3 + 7 with quizartinib (QuANTUM-First; NCT02668653) in patients with newly diagnosed FLT3-ITDmut AML eligible for induction therapy recently completed accrual.